Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

, GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

16:13
04/19/18
04/19
16:13
04/19/18
16:13

Theravance Biopharma reports publication of study of Treleggy Ellipta in COPD

Theravance Biopharma (TBPH) highlighted the publication in the New England Journal of Medicine of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innovivam formerly Theravance, Inc. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Those royalties are upward-tiering from 6.5% to 10%, resulting in cash flows to Theravance Biopharma of approximately 5.5% to 8.5% of worldwide net sales of Trelegy Ellipta. Results from additional secondary and other endpoints published in the NEJM include: a statistically significant 34% reduction in COPD hospitalizations for Trelegy compared to Anoro and a reduction of 13% compared to Relvar/Breo which was not statistically significant ; a 42.1% reduction in the risk of on-treatment all-cause mortality was observed for Trelegy compared to Anoro. The safety profile of single inhaler triple therapy was consistent with the safety profile of the individual components. Trelegy Ellipta is approved in Europe as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA. The product is also approved for use in the US for the long-term, once-daily, maintenance treatment of COPD patients who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse. Regulatory applications for Trelegy Ellipta have been submitted and are undergoing assessments in a number of other countries.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

  • 20

    Apr

  • 23

    Apr

  • 25

    Apr

  • 08

    May

  • 18

    May

  • 21

    May

  • 13

    Nov

TBPH Theravance Biopharma
$22.18

-0.65 (-2.85%)

05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
03/29/18
PIPR
03/29/18
INITIATION
Target $45
PIPR
Overweight
Theravance Biopharma assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Theravance Biopharma with an Overweight rating and $45 price target. The company's respiratory products Trelegy and revefenacin "provide solid valuation support with the potential for significant upside" from its proprietary 1473/JAK and 9855/nOH development candidate, the analyst contends. He has confidence in the Trelegy launch and revefenacin approval and recommends investors buy the shares.
GSK GlaxoSmithKline
$39.85

-0.6 (-1.48%)

03/22/18
MSCO
03/22/18
UPGRADE
MSCO
Equal Weight
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier upgraded GlaxoSmithKline to Equal Weight and raised his price target for the shares to GBP 14 from GBP 13. The company's capital allocation strategy and operational repositioning show "clear signs of improvement," Meunier tells investors in a research note. Further, the analyst believes comments by the CEO suggest a large consumer deal is less likely than several months ago, which he believes reduces the risk of a dividend cut.
03/22/18
03/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Axle (AXL) and BorgWarner (BWA) were double-upgraded to Overweight from Underweight at Morgan Stanley. 2. GlaxoSmithKline (GSK) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Vincent Meunier saying the company's capital allocation strategy and operational repositioning show "clear signs of improvement." 3. General Mills (GIS) upgraded to Hold from Sell at Societe Generale with analyst Warren Ackerman citing valuation for the upgrade following yesterday's post-earnings selloff. 4. Pandora (P) upgraded to Strong Buy from Market Perform at Raymond James with analyst Justin Patterson saying AdsWizz will expand TAM by 2x to $28B, accelerate tech initiatives, materially expand reach, and could be worth approximately $4 per share. 5. Southwest (LUV) upgraded to Buy on valuation at Buckingham with analyst Daniel McKenzie saying shares are oversold and maintained a $70 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
EXAN
04/04/18
UPGRADE
EXAN
Outperform
GlaxoSmithKline upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Kerry Holford upgraded GlaxoSmithKline to Outperform with an increased price target of GBP 16.30.
04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

OSK

Oshkosh

$64.85

0.83 (1.30%)

11:40
12/17/18
12/17
11:40
12/17/18
11:40
Conference/Events
Oshkosh management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

11:36
12/17/18
12/17
11:36
12/17/18
11:36
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

11:36
12/17/18
12/17
11:36
12/17/18
11:36
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

OEC

Orion Engineered

$24.31

0.125 (0.52%)

11:35
12/17/18
12/17
11:35
12/17/18
11:35
Conference/Events
Orion Engineered management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

PG

Procter & Gamble

$94.68

-1.97 (-2.04%)

11:35
12/17/18
12/17
11:35
12/17/18
11:35
Options
Procter & Gamble put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

OUT

Outfront Media

$19.12

-0.23 (-1.19%)

11:33
12/17/18
12/17
11:33
12/17/18
11:33
Hot Stocks
Outfront Media announces Lowell Simpson hired as Chief Information Officer »

Outfront Media announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$170.18

0.1 (0.06%)

11:28
12/17/18
12/17
11:28
12/17/18
11:28
Recommendations
Vertex analyst commentary  »

Vertex CFO resignation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEX

Kirby

$69.66

0.63 (0.91%)

11:26
12/17/18
12/17
11:26
12/17/18
11:26
Conference/Events
Kirby management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

ATNX

Athenex

$12.06

0.09 (0.75%)

11:25
12/17/18
12/17
11:25
12/17/18
11:25
Conference/Events
Athenex to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

OVID

Ovid Therapeutics

$3.01

(0.00%)

11:21
12/17/18
12/17
11:21
12/17/18
11:21
Recommendations
Ovid Therapeutics analyst commentary  »

Ovid shares should be up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

IGT

International Game

$15.93

0.39 (2.51%)

11:20
12/17/18
12/17
11:20
12/17/18
11:20
Conference/Events
International Game management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

  • 19

    Dec

PUMP

ProPetro Holding

$15.13

0.42 (2.86%)

11:20
12/17/18
12/17
11:20
12/17/18
11:20
Options
Call spreads in ProPetro Holding Corp as a bullish position is adjusted »

Call spreads in ProPetro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
12/17/18
12/17
11:17
12/17/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
12/17/18
12/17
11:16
12/17/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
12/17/18
12/17
11:15
12/17/18
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
12/17/18
12/17
11:15
12/17/18
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

ACHC

Acadia

$27.38

-1.52 (-5.26%)

11:12
12/17/18
12/17
11:12
12/17/18
11:12
Recommendations
Acadia analyst commentary  »

Acadia near-term LBO less…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.78

-0.24 (-0.17%)

, TWTR

Twitter

$34.91

-0.96 (-2.68%)

11:10
12/17/18
12/17
11:10
12/17/18
11:10
Hot Stocks
Walt Mossberg says he's quitting Facebook, Instagram, Messenger »

Walt Mossberg, the…

FB

Facebook

$143.78

-0.24 (-0.17%)

TWTR

Twitter

$34.91

-0.96 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$228.98

-1.02 (-0.44%)

11:10
12/17/18
12/17
11:10
12/17/18
11:10
Options
Adobe attracts a bullish option play as shares extend losses »

Adobe attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 07

    Jan

KEYS

Keysight Technologies

$60.86

-0.64 (-1.04%)

11:04
12/17/18
12/17
11:04
12/17/18
11:04
Hot Stocks
Keysight Technologies, MediaTek collaborate for 5G multimode devices »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$71.02

-1.52 (-2.10%)

11:00
12/17/18
12/17
11:00
12/17/18
11:00
Options
Nike calls bought ahead of earnings »

Nike calls bought ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

10:55
12/17/18
12/17
10:55
12/17/18
10:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD topped…

AMZN

Amazon.com

$1,555.76

-36.38 (-2.29%)

10:50
12/17/18
12/17
10:50
12/17/18
10:50
Options
Multimillion dollar put buyer in Amazon »

Multimillion dollar put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 07

    Jan

SHPG

Shire

$170.90

-4.03 (-2.30%)

, MYL

Mylan

$29.13

0.08 (0.28%)

10:49
12/17/18
12/17
10:49
12/17/18
10:49
Hot Stocks
Mylan announces U.S. launch of generic Lialda delayed-release tablets »

Mylan N.V. (MYL)…

SHPG

Shire

$170.90

-4.03 (-2.30%)

MYL

Mylan

$29.13

0.08 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

  • 22

    Dec

10:45
12/17/18
12/17
10:45
12/17/18
10:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.